James Williams

Summary

Publications

  1. ncbi pDNAVACCultra vector family: high throughput intracellular targeting DNA vaccine plasmids
    James A Williams
    Nature Technology Corporation, 4701 Innovation Drive, Lincoln, NE 68521, USA
    Vaccine 24:4671-6. 2006
  2. ncbi Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production
    James A Williams
    Nature Technology Corporation, Lincoln, NE 68521, USA
    Biotechnol Adv 27:353-70. 2009
  3. ncbi Strain engineering by genome mass transfer: efficient chromosomal trait transfer method utilizing donor genomic DNA and recipient recombineering hosts
    James A Williams
    Nature Technology Corporation, 4701 Innovation Drive, Lincoln, NE 68521, USA
    Mol Biotechnol 43:41-51. 2009
  4. ncbi Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine
    Jeremy M Luke
    Nature Technology Corporation, Lincoln, Nebraska 68521, USA
    J Virol 85:1370-83. 2011
  5. ncbi Inducible Escherichia coli fermentation for increased plasmid DNA production
    Aaron E Carnes
    Nature Technology Corporation, 4701 Innovation Drive, Lincoln, NE 68521, USA
    Biotechnol Appl Biochem 45:155-66. 2006
  6. ncbi Use of an adaptation of a commercially available PCR assay aimed at diagnosis of chlamydia and gonorrhea to detect Trichomonas vaginalis in urogenital specimens
    Barbara Van Der Pol
    Division of Infectious Diseases, Indiana University Scool of Medicine, Indianapolis, IN 46202, USA
    J Clin Microbiol 44:366-73. 2006

Research Grants

  1. Antisense inhibitors for enhanced plasmid production
    Jim Williams; Fiscal Year: 2005
  2. eukaryotic expression vectors resistant to transgene silencing
    James Williams; Fiscal Year: 2007
  3. Rapid deployment DNA vaccine for pandemic influenza
    James Williams; Fiscal Year: 2007
  4. Chimeric enzyme for nucleic acid autohydrolysis
    James Williams; Fiscal Year: 2007

Collaborators

  • Aaron E Carnes
  • Jeremy M Luke
  • Barbara Van Der Pol
  • John S Errett
  • Clague P Hodgson
  • Jonas Soderholm
  • Gregory G Simon
  • Michael Gale
  • J Thomas August
  • Colleen S Kraft

Detail Information

Publications6

  1. ncbi pDNAVACCultra vector family: high throughput intracellular targeting DNA vaccine plasmids
    James A Williams
    Nature Technology Corporation, 4701 Innovation Drive, Lincoln, NE 68521, USA
    Vaccine 24:4671-6. 2006
    ..The ability to control expression and trafficking is intended to provide a rapid, rational approach to cancer therapy and emerging infectious diseases...
  2. ncbi Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production
    James A Williams
    Nature Technology Corporation, Lincoln, NE 68521, USA
    Biotechnol Adv 27:353-70. 2009
    ..Utilizing recently developed low metabolic burden seed stock and fermentation strategies, optimized vectors can now be manufactured in high yields exceeding 2 g/L, with specific plasmid yields of 5% total dry cell weight...
  3. ncbi Strain engineering by genome mass transfer: efficient chromosomal trait transfer method utilizing donor genomic DNA and recipient recombineering hosts
    James A Williams
    Nature Technology Corporation, 4701 Innovation Drive, Lincoln, NE 68521, USA
    Mol Biotechnol 43:41-51. 2009
    ..This allows unprecedented simplicity and speed for rational design engineering of complex phenotypes in industrial strains...
  4. ncbi Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine
    Jeremy M Luke
    Nature Technology Corporation, Lincoln, Nebraska 68521, USA
    J Virol 85:1370-83. 2011
    ..This demonstrates that DNA vaccine potency may be augmented by the incorporation of RIG-I-activating immunostimulatory RNA into the vector backbone...
  5. ncbi Inducible Escherichia coli fermentation for increased plasmid DNA production
    Aaron E Carnes
    Nature Technology Corporation, 4701 Innovation Drive, Lincoln, NE 68521, USA
    Biotechnol Appl Biochem 45:155-66. 2006
    ..This 5-10-fold increase in plasmid yield dramatically decreases plasmid manufacturing costs and improves the effectiveness of downstream purification by reducing the fraction of impurities...
  6. ncbi Use of an adaptation of a commercially available PCR assay aimed at diagnosis of chlamydia and gonorrhea to detect Trichomonas vaginalis in urogenital specimens
    Barbara Van Der Pol
    Division of Infectious Diseases, Indiana University Scool of Medicine, Indianapolis, IN 46202, USA
    J Clin Microbiol 44:366-73. 2006
    ..Using samples prepared for, and reagents from, the C. trachomatis-N. gonorrhoeae PCR assay allowed incorporation of T. vaginalis PCR diagnosis into routine clinical testing...

Research Grants5

  1. Antisense inhibitors for enhanced plasmid production
    Jim Williams; Fiscal Year: 2005
    ..The economic benefits and potential market size for the resulting products can be readily appreciated. The likelihood of a commercially useful and valuable product resulting from the proposed work is considered high. ..
  2. eukaryotic expression vectors resistant to transgene silencing
    James Williams; Fiscal Year: 2007
    ..In Phase II, NTC will make the vectors available for licensing, and will apply the technology to develop cell culture based methods for manufacture of glycoproteins such as FSH and biogeneric drugs. ..
  3. Rapid deployment DNA vaccine for pandemic influenza
    James Williams; Fiscal Year: 2007
    ..This proposal is aimed at developing novel influenza vaccines to replace egg based vaccine production technologies and as such is responsive to NIAID's high priority influenza research areas, as outlined in NOT-AI-06-011. ..
  4. Chimeric enzyme for nucleic acid autohydrolysis
    James Williams; Fiscal Year: 2007
    ..This technology will be licensed to plasmid DNA manufacturers; one such commercialization channel has already been identified. ..